PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v9i4.11502ArticleNeoadjuvant Therapy with Alectinib for Non-Small Cell Lung Cancer with Pleural Metastasis: A Case Reporthttps://artdesignp.com/journal/PAR/9/4/10.26689/par.v9i4.11502ChenXuewei,ChenYingxin,FuJunjun,YeZhan,LinAo,XieJieyu,LeiZhihao,SunFeie,ZhangXin2025942025-08-05Background: The prognosis of stage IV non-small cell lung cancer(NSCLC) with pleural metastasis is poor, with a 5-year survival rate of only 2% to 4% for patients, with the median survival was 9.5-11.5 months. According to the “NCCN Lung Cancer Guidelines,” stage IV NSCLC lung cancer is a contraindication for surgery. It is recommended to adopt a standard treatment plan mainly based on chemotherapy or targeted therapy with EGFR-TKIs. However, Neoadjuvant therapy with alectinib for non-small cell lung cancer with pleural metastasis is rarely reported. Case presentation: A 41-year-old Asian male patient presented with a persistent cough for one month. A chest computed tomography (CT) scan conducted two years prior revealed that a nodular radiative anomalous concentrated shadow was observed in the inferior tongue segment of the upper lobe of the left lung, approximately 2.2 × 1.6 × 1.2 cm in size, with a SUVmax of about 5.5. Two small nodular shadows were seen beside the disease in the inferior lingual segment of the upper lobe of the left lung, with the larger one having a diameter of approximately 0.6 cm. Multiple lymph node metastases in the left hilum and mediastinum; Multiple metastases of the left pleura and a small amount of pleural effusion on the left side. The patient began to receive 2 courses of chemotherapy and targeted therapy (pemetrexed+ carboplatin+crizotinib) and 1 course of chemotherapy and other targeted therapy (pemetrexed+ carboplatin+ alectinib). The result of re-examination of CT demonstrated that peripheral lung cancer in the lower lingual segment of the left upper lung is approximately 0.8 × 0.9 cm in size, slightly smaller than before. A thoracoscopic lobectomy was performed, and the pulmonary bulla was removed concurrently. Pathological examination confirmed non-small cell lung carcinoma (NSCLC) in the mass. Patient discharged on the 7th day after the operation and received 2 courses of chemotherapy (pemetrexed + carboplatin) and had been receiving alectinib targeted drug treatment all along for over 5 years. However, the patient stopped taking the medicine on his own for half a year. Though in the recent CT examination, the result demonstrated no recurrence and metastasis and the patient has been clinically cured. Unfortunately, the results of brain magnetic resonance imaging suggested that multiple brain metastases of lung cancer occurred, and the patient began taking the third-generation ALK-targeted drug lorlatinib. Conclusions: The patient with stage IV non-small cell lung cancer (NSCLC) presenting with pleural metastasis received neoadjuvant alectinib therapy and underwent thoracoscopic lobectomy, which resulted in significant therapeutic effects and fulfilled the criteria for clinical cure. This case highlights the potential for improved preventative strategies and treatment approaches in similar patients.

Ettinger D, Wood D, Aisner D, et al., 2023, NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. Journal of the National Comprehensive Cancer Network, 21(4): 340–350.

Ichinose Y, Tsuchiya R, Koike T, et al., 2001, Prognosis of Resected Non-Small Cell Lung Cancer Patients with Carcinomatous Pleuritis of Minimal Disease. Lung Cancer, 32(1): 55–60.

Xu Y, Chen N, Wang Z, et al., 2016, Should Primary Tumor Be Resected for Non-Small Cell Lung Cancer with Malignant Pleural Disease Unexpectedly Found during Operation?–A Systemic Review and Meta-Analysis. Journal of Thoracic Disease, 8(10): 2843–2852.

Iida T, Shiba M, Yoshino I, et al., 2015, Surgical Intervention for Non-Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004. Journal of Thoracic Oncology, 10(7): 1076–1082.

Go T, Misaki N, Matsuura N, et al., 2015, Role of Surgery in Multi-Modality Treatment for Carcinomatous Pleuritis in Patients with Non-Small Cell Lung Cancer. Surgery Today, 45(2): 197–202.

Li S, Yang X, Zhang S, et al., 2020, The Prognostic Analysis of Lung Cancer Patients with Occult Malignant Pleural Disease at Thoracotomy. Translational Cancer Research, 9(3): 1689–1697.

Fukuse T, Hirata T, Tanaka F, et al., 2001, The Prognostic Significance of Malignant Pleural Effusion at the Time of Thoracotomy in Patients with Non-Small Cell Lung Cancer. Lung Cancer, 34(1): 75–81.

Ng K, Sun C, Boom K, et al., 2020, Prognostic Factors of EGFR-Mutated Metastatic Adenocarcinoma of Lung. European Journal of Radiology, 123: 108780.

Soria J, Ohe Y, Vansteenkiste J, et al., 2018, Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 378(2): 113–125.

Sequist L, Yang J, Yamamoto N, et al., 2013, Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients with Metastatic Lung Adenocarcinoma with EGFR Mutations. Journal of Clinical Oncology, 31(27): 3327–3334.

Greenhalgh J, Boland A, Bates V, et al., 2021, First-Line Treatment of Advanced Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Squamous Non-Small Cell Lung Cancer. The Cochrane Database of Systematic Reviews, 3(3): CD010383.

Yun J, Kim M, Choi C, et al., 2018, Surgical Outcomes after Pulmonary Resection for Non-Small Cell Lung Cancer with Localized Pleural Seeding First Detected during Surgery. The Thoracic and Cardiovascular Surgeon, 66(2): 142–149.

Wu Y, Dziadziuszko R, Ahn J, et al., 2024, Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 390(14): 1265–1276.

Garcia C, Abrahami D, Polli A, et al., 2024, Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons. Clinical Lung Cancer, 25(7): 634–642.

Jeon H, Wang S, Song J, et al., 2025, Update 2025: Management of Non‑Small-Cell Lung Cancer. Lung, 203(1): 53.

Liu Y, 2018, Small Cell Lung Cancer Transformation from EGFR-Mutated Lung Adenocarcinoma: A Case Report and Literatures Review. Cancer Biology & Therapy, 19(6): 445–449.

Chang J, Huang C, Fang Y, et al., 2023, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: Real-World Data from Taiwan. Thoracic Cancer, 14(1): 12–23.

Taniguchi Y, Tamiya A, Nakahama K, et al., 2017, Impact of Metastatic Status on the Prognosis of EGFR Mutation-Positive Non-Small Cell Lung Cancer Patients Treated with First-Generation EGFR-Tyrosine Kinase Inhibitors. Oncology Letters, 14(6): 7589–7596.

Pan Y, Yan L, Gu Y, et al., 2025, The Effectiveness of Sequential Afatinib and Furmonertinib in an Advanced Lung Adenocarcinoma with Rare Compound EGFR Mutation (L833V/H835L). Anti-Cancer Drugs, 36(4): 355–358.